DNTH
Dianthus Therapeutics, Inc.
Price Chart
Latest Quote
$82.49
+0.60 (+0.73%)
Current Price
| Previous Close | $81.89 |
| Open | $83.64 |
| Day High | $84.82 |
| Day Low | $79.79 |
| Volume | 2,478,036 |
Stock Information
| Shares Outstanding | 54.67M |
| Total Debt | $1.36M |
| Cash Equivalents | $1.11B |
| Revenue | $1.34M |
| Net Income | $-173.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.51B |
| EPS (TTM) | $-4.23 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.40B |
| Sales | $1.34M |
| Income | $-173.66M |
| Book/sh | $22.01 |
| Cash/sh | $20.33 |
| Employees | 92 |
Financial Ratios
| Quick Ratio | 29.06 |
| Current Ratio | 29.25 |
| Debt/Eq | 0.11 |
Returns & Margins
| ROA | -14.99% |
| ROE | -22.70% |
| Gross Margin | 100.00% |
| Operating Margin | -10050.32% |
Ownership
| Insider Ownership | 0.13% |
| Institutional Ownership | 120.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -17.74 |
| P/S | 3375.31 |
| P/B | 3.75 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $127.67 |
Technical Indicators
| SMA20 | $84.03 |
| SMA50 | $86.79 |
| SMA200 | $57.46 |
| RSI | 38.27 |
| ATR | 6.0736 |
| Shares Float | 54.60M |
| Short Float | 14.09% |
| Short Ratio | 12.70 |
| Volatility | 0.07 |
| Rel Volume | 2.27 |
Performance History
| Week | +7.90% |
| Month | -3.71% |
| Quarter | +3.11% |
| 6 Months | +99.25% |
| YTD | +107.89% |
| Year | +377.65% |
| 3 Years | +636.52% |
| 5 Years | -55.48% |
| 10 Years | -64.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $82.49 | 2,478,000 |
| 2026-06-17 | $81.89 | 870,300 |
| 2026-06-16 | $78.88 | 910,500 |
| 2026-06-15 | $82.51 | 764,500 |
| 2026-06-12 | $82.07 | 1,380,700 |
| 2026-06-11 | $76.45 | 1,441,800 |
| 2026-06-10 | $76.42 | 4,705,500 |
| 2026-06-09 | $84.57 | 954,500 |
| 2026-06-08 | $81.22 | 559,600 |
| 2026-06-05 | $80.51 | 835,900 |
| 2026-06-04 | $84.13 | 901,600 |
| 2026-06-03 | $84.97 | 580,900 |
| 2026-06-02 | $81.57 | 1,057,900 |
| 2026-06-01 | $89.45 | 604,300 |
| 2026-05-29 | $93.01 | 1,248,700 |
| 2026-05-28 | $90.86 | 612,500 |
| 2026-05-27 | $86.67 | 560,400 |
| 2026-05-26 | $86.82 | 377,700 |
| 2026-05-22 | $86.48 | 469,800 |
| 2026-05-21 | $89.63 | 514,800 |
| 2026-05-20 | $88.72 | 677,000 |
| 2026-05-19 | $85.67 | 531,800 |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
đ° Latest News
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Zacks âĸ 2026-06-17T14:29:00Z
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
Simply Wall St. âĸ 2026-06-15T11:09:17Z
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
Stocktwits âĸ 2026-06-12T21:13:58Z
Sanofi, An Argenx Rival, Bites The Dust â But A Third Biotech Took The Biggest Hit
Investor's Business Daily âĸ 2026-06-10T20:48:19Z
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Barchart âĸ 2026-06-10T20:38:17Z
Stocks Resume Decline as Chipmakers and AI Companies Fall
Barchart âĸ 2026-06-10T15:21:45Z
Stocks Fall on Weakness in Tech and Trucking Companies
Barchart âĸ 2026-06-10T14:09:04Z
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative
Simply Wall St. âĸ 2026-06-10T00:17:36Z
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
Insider Monkey âĸ 2026-06-05T15:55:45Z
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
Insider Monkey âĸ 2026-06-03T17:15:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,036,000 | $6,235,000 | $2,826,000 | $6,417,000 |
| Operating Revenue | $2,036,000 | $6,235,000 | $2,826,000 | $6,417,000 |
| Expenses | ||||
| Total Expenses | $179,969,000 | $108,099,000 | $51,000,000 | $36,122,000 |
| Other Income Expense | $-523,000 | $-470,000 | $-145,000 | $84,000 |
| Other Non Operating Income Expenses | $-974,000 | $-554,000 | $-60,000 | $-52,000 |
| Net Non Operating Interest Income Expense | $16,119,000 | $17,365,000 | $4,764,000 | $1,145,000 |
| Operating Expense | $179,969,000 | $108,099,000 | $51,000,000 | $36,122,000 |
| General And Administrative Expense | $34,331,000 | $24,994,000 | $18,159,000 | $6,743,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Net Interest Income | $16,119,000 | $17,365,000 | $4,764,000 | $1,145,000 |
| Interest Income | $16,119,000 | $17,365,000 | $4,764,000 | $1,145,000 |
| Normalized Income | $-162,788,000 | $-85,053,000 | $-43,470,000 | $-28,612,000 |
| Net Income From Continuing And Discontinued Operation | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Total Operating Income As Reported | $-177,933,000 | $-101,864,000 | $-48,174,000 | $-29,705,000 |
| Net Income Common Stockholders | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Net Income | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Net Income Including Noncontrolling Interests | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Net Income Continuous Operations | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Pretax Income | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Interest Income Non Operating | $16,119,000 | $17,365,000 | $4,764,000 | $1,145,000 |
| Operating Income | $-177,933,000 | $-101,864,000 | $-48,174,000 | $-29,705,000 |
| Per Share | ||||
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 | $-1.92 |
| Basic EPS | $-4.20 | $-2.55 | $-8.45 | $-1.92 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-177,956,000 | $-101,536,000 | $-47,734,000 | $-29,694,000 |
| Total Unusual Items | $451,000 | $84,000 | $-85,000 | $136,000 |
| Total Unusual Items Excluding Goodwill | $451,000 | $84,000 | $-85,000 | $136,000 |
| Reconciled Depreciation | $428,000 | $412,000 | $355,000 | $147,000 |
| EBITDA (Bullshit earnings) | $-177,505,000 | $-101,452,000 | $-47,819,000 | $-29,558,000 |
| EBIT | $-177,933,000 | $-101,864,000 | $-48,174,000 | $-29,705,000 |
| Diluted Average Shares | $38,617,580 | $33,313,849 | $5,153,711 | $14,817,700 |
| Basic Average Shares | $38,617,580 | $33,313,849 | $5,153,711 | $14,817,700 |
| Diluted NI Availto Com Stockholders | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Gain On Sale Of Security | $451,000 | $84,000 | $-85,000 | $136,000 |
| Research And Development | $145,638,000 | $83,105,000 | $32,841,000 | $29,379,000 |
| Selling General And Administration | $34,331,000 | $24,994,000 | $18,159,000 | $6,743,000 |
| Other Gand A | $34,331,000 | $24,994,000 | $18,159,000 | $6,743,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $493,401,000 | $352,477,000 | $168,870,000 | $73,656,000 |
| Total Assets | $530,922,000 | $374,008,000 | $179,405,000 | $83,110,000 |
| Total Non Current Assets | $121,484,000 | $93,104,000 | $1,954,000 | $1,077,000 |
| Other Non Current Assets | $9,716,000 | $9,629,000 | $1,154,000 | $121,000 |
| Investmentin Financial Assets | $110,135,000 | $81,728,000 | - | - |
| Current Assets | $409,438,000 | $280,904,000 | $177,451,000 | $82,033,000 |
| Other Current Assets | $86,000 | $355,000 | $504,000 | $53,000 |
| Prepaid Assets | $5,005,000 | $4,501,000 | $2,751,000 | $852,000 |
| Receivables | $52,000 | $807,000 | $478,000 | $5,638,000 |
| Accounts Receivable | $52,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $404,295,000 | $275,241,000 | $173,718,000 | $75,490,000 |
| Cash And Cash Equivalents | $51,087,000 | $22,792,000 | $132,325,000 | $15,365,000 |
| Other Receivables | - | - | $184,000 | $938,000 |
| Debt | ||||
| Total Debt | $1,386,000 | $1,491,000 | $585,000 | $788,000 |
| Long Term Debt And Capital Lease Obligation | $1,019,000 | $1,171,000 | $168,000 | $438,000 |
| Current Debt And Capital Lease Obligation | $367,000 | $320,000 | $417,000 | $350,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $37,521,000 | $21,531,000 | $10,535,000 | $9,454,000 |
| Total Non Current Liabilities Net Minority Interest | $6,789,000 | $3,079,000 | $904,000 | $1,229,000 |
| Non Current Deferred Liabilities | $5,770,000 | $1,908,000 | $736,000 | $791,000 |
| Current Liabilities | $30,732,000 | $18,452,000 | $9,631,000 | $8,225,000 |
| Current Deferred Liabilities | $1,188,000 | $479,000 | $100,000 | $100,000 |
| Payables And Accrued Expenses | $19,660,000 | $12,499,000 | $3,753,000 | $5,691,000 |
| Payables | $9,725,000 | $4,579,000 | $2,610,000 | $1,167,000 |
| Accounts Payable | $9,725,000 | $4,579,000 | $2,610,000 | $1,167,000 |
| Equity | ||||
| Common Stock Equity | $493,401,000 | $352,477,000 | $168,870,000 | $-44,368,000 |
| Total Equity Gross Minority Interest | $493,401,000 | $352,477,000 | $168,870,000 | $73,656,000 |
| Stockholders Equity | $493,401,000 | $352,477,000 | $168,870,000 | $73,656,000 |
| Gains Losses Not Affecting Retained Earnings | $489,000 | $106,000 | $47,000 | $-161,000 |
| Other Equity Adjustments | $489,000 | $106,000 | $47,000 | $-161,000 |
| Retained Earnings | $-336,729,000 | $-174,392,000 | $-89,423,000 | $-45,868,000 |
| Preferred Stock Equity | - | - | - | $118,024,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $21,348,000 |
| Other | ||||
| Ordinary Shares Number | $43,223,090 | $31,115,341 | $14,817,696 | $14,817,700 |
| Share Issued | $43,223,090 | $31,115,341 | $14,817,696 | $14,817,700 |
| Tangible Book Value | $493,401,000 | $352,477,000 | $168,870,000 | $-44,368,000 |
| Invested Capital | $493,401,000 | $352,477,000 | $168,870,000 | $-44,368,000 |
| Working Capital | $378,706,000 | $262,452,000 | $167,820,000 | $73,808,000 |
| Capital Lease Obligations | $1,386,000 | $1,491,000 | $585,000 | $788,000 |
| Total Capitalization | $493,401,000 | $352,477,000 | $168,870,000 | $73,656,000 |
| Additional Paid In Capital | $829,598,000 | $526,732,000 | $258,231,000 | $1,661,000 |
| Capital Stock | $43,000 | $31,000 | $15,000 | $118,024,000 |
| Common Stock | $43,000 | $31,000 | $15,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $118,024,000 |
| Non Current Deferred Revenue | $5,770,000 | $1,908,000 | $736,000 | $791,000 |
| Long Term Capital Lease Obligation | $1,019,000 | $1,171,000 | $168,000 | $438,000 |
| Current Deferred Revenue | $1,188,000 | $479,000 | $100,000 | $100,000 |
| Current Capital Lease Obligation | $367,000 | $320,000 | $417,000 | $350,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,517,000 | $5,154,000 | $5,361,000 | $2,084,000 |
| Current Accrued Expenses | $9,935,000 | $7,920,000 | $1,143,000 | $4,524,000 |
| Investments And Advances | $110,135,000 | $81,728,000 | $0 | - |
| Available For Sale Securities | $110,135,000 | $81,728,000 | - | - |
| Net PPE | $1,633,000 | $1,747,000 | $800,000 | $956,000 |
| Accumulated Depreciation | $-304,000 | $-193,000 | $-97,000 | $-30,000 |
| Gross PPE | $1,937,000 | $1,940,000 | $897,000 | $986,000 |
| Other Properties | $1,337,000 | $1,553,000 | $615,000 | $814,000 |
| Machinery Furniture Equipment | $600,000 | $387,000 | $282,000 | $172,000 |
| Duefrom Related Parties Current | $0 | $807,000 | $294,000 | $4,700,000 |
| Other Short Term Investments | $353,208,000 | $252,449,000 | $41,393,000 | $60,125,000 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-129,273,000 | $-78,285,000 | $-36,971,000 | $-29,209,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-129,060,000 | $-78,180,000 | $-36,861,000 | $-29,070,000 |
| Cash Flow From Continuing Operating Activities | $-129,060,000 | $-78,180,000 | $-36,861,000 | $-29,070,000 |
| Operating Gains Losses | $-507,000 | $-148,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-213,000 | $-105,000 | $-110,000 | $-139,000 |
| Investing Cash Flow | $-122,833,000 | $-286,812,000 | $20,253,000 | $-59,819,000 |
| Cash Flow From Continuing Investing Activities | $-122,833,000 | $-286,812,000 | $20,253,000 | $-59,819,000 |
| Capital Expenditure Reported | $-213,000 | $-105,000 | $-110,000 | $-139,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $272,268,000 | $269,198,000 | $72,000,000 | $100,000,000 |
| Financing Cash Flow | $280,125,000 | $255,623,000 | $133,574,000 | $96,676,000 |
| Cash Flow From Continuing Financing Activities | $280,125,000 | $255,623,000 | $133,574,000 | $96,676,000 |
| Net Other Financing Charges | $-364,000 | $-14,665,000 | $61,569,000 | $-3,324,000 |
| Net Common Stock Issuance | $272,268,000 | $269,198,000 | $72,000,000 | $0 |
| Common Stock Issuance | $272,268,000 | $269,198,000 | $72,000,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $100,000,000 |
| Preferred Stock Issuance | - | - | $0 | $100,000,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $51,254,000 | $23,022,000 | $132,391,000 | $15,425,000 |
| Beginning Cash Position | $23,022,000 | $132,391,000 | $15,425,000 | $7,638,000 |
| Changes In Cash | $28,232,000 | $-109,369,000 | $116,966,000 | $7,787,000 |
| Proceeds From Stock Option Exercised | $8,221,000 | $1,090,000 | $5,000 | $0 |
| Net Investment Purchase And Sale | $-122,620,000 | $-286,707,000 | $20,363,000 | $-59,680,000 |
| Sale Of Investment | $312,393,000 | $127,000,000 | $77,785,000 | $2,000,000 |
| Purchase Of Investment | $-435,013,000 | $-413,707,000 | $-57,422,000 | $-61,680,000 |
| Change In Working Capital | $16,726,000 | $-351,000 | $4,862,000 | $-1,653,000 |
| Change In Other Working Capital | $4,571,000 | $1,551,000 | $-55,000 | $891,000 |
| Change In Other Current Assets | $358,000 | $-8,163,000 | $-1,027,000 | $-31,000 |
| Change In Payables And Accrued Expense | $11,277,000 | $8,191,000 | $661,000 | $2,280,000 |
| Change In Payable | $11,277,000 | $8,191,000 | $661,000 | $2,280,000 |
| Change In Account Payable | $11,277,000 | $8,191,000 | $661,000 | $2,280,000 |
| Change In Prepaid Assets | $-235,000 | $-1,601,000 | $123,000 | $-631,000 |
| Change In Receivables | $755,000 | $-329,000 | $5,160,000 | $-4,162,000 |
| Changes In Account Receivables | $-52,000 | $0 | - | - |
| Stock Based Compensation | $22,793,000 | $12,894,000 | $2,900,000 | $1,518,000 |
| Amortization Of Securities | $-6,163,000 | $-6,018,000 | $-1,423,000 | $-606,000 |
| Depreciation Amortization Depletion | $428,000 | $412,000 | $355,000 | $147,000 |
| Depreciation And Amortization | $428,000 | $412,000 | $355,000 | $147,000 |
| Depreciation | $428,000 | $412,000 | $355,000 | $147,000 |
| Gain Loss On Investment Securities | $-507,000 | $-148,000 | - | - |
| Net Income From Continuing Operations | $-162,337,000 | $-84,969,000 | $-43,555,000 | $-28,476,000 |
| Repayment Of Debt | - | $0 | $-377,000 | $0 |
| Issuance Of Debt | - | $0 | $377,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $0 | $0 |
| Net Long Term Debt Issuance | - | $0 | $0 | $0 |
| Long Term Debt Payments | - | $0 | $-377,000 | $0 |
| Long Term Debt Issuance | - | $0 | $377,000 | $0 |
| Other Non Cash Items | - | $-148,000 | - | - |
Fetched: 2026-06-17